[Should we treat patients over 65 years with acute myeloblastic leukemia?]. - TheREx : Thérapeutique Recombinante Expérimentale Accéder directement au contenu
Article Dans Une Revue Revue du Praticien (La) Année : 2010

[Should we treat patients over 65 years with acute myeloblastic leukemia?].

Martin Carré
  • Fonction : Auteur
Jean-Yves Cahn
  • Fonction : Auteur

Résumé

The incidence of acute myeloblastic leukemia increases with age. The unfavorable biology of the disease, comorbidities, and significant side effects of the intensive treatment make treatment decisions difficult. New and less toxic targeted approaches are under investigations in this setting and the main problem remains to determine which strategy for patients over 65 years of age. Some of them will be treated successfully using intensive chemotherapy, while a majority of them will fail. Older patients are heterogeneous and enrolling them in investigational therapy is justified, according to proven methods to stratify them.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-00849652 , version 1 (31-07-2013)

Identifiants

  • HAL Id : hal-00849652 , version 1
  • PUBMED : 21425545

Citer

Martin Carré, Jean-Yves Cahn. [Should we treat patients over 65 years with acute myeloblastic leukemia?].. Revue du Praticien (La), 2010, 60 (10), pp.1423-6. ⟨hal-00849652⟩
1287 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More